Cerebral energy state and glycolytic metabolism during XXXX infusion in the @entity35 .

@entity410 @entity1734 @entity2944 @entity1027 @entity6546 @entity3303 @entity35 @entity857 @entity13147 @entity2388
The effects of intravenously administered @entity3303 on the cerebral cortical energy state and glycolytic metabolism were studied in @entity35 . In one series, @entity35 were divided into five groups according to EEG patterns, i.e., control, desynchronized, synchronized, @entity410 (1-min duration) and recovery groups. With @entity3303 infusion (0.75 mg/min), there were no significant changes from the control group in the cerebral energy state except for a modest increase in @entity1734 (PCr) in the @entity410 group and a small decrease in @entity857 in the non- @entity410 groups. The cerebral energy charge remained unchanged. Lactate and @entity2388 significantly decreased in the non- @entity410 groups. In a second series, @entity35 were divided into five groups, i.e., control, @entity3303 @entity410 groups (5-min duration, 1.5 mg/min) at @entity13147 , normocapnia and @entity2944 , and a @entity1027 (1.2 mg/kg) @entity410 group. The metabolic changes during @entity3303 @entity410 were essentially the same as those observed in the @entity410 group in the first series. However, the increase in PCr during @entity3303 @entity410 was significant only in the hypocapnic and the normocapnic groups. @entity1027 -induced @entity410 were accompanied by a significant decrease in high energy @entity6546 . In summary, neither a non- @entity410 nor- @entity410 dose of @entity3303 caused any reduction in the cerebral energy charge nor was there any evidence of increased anaerobic metabolism in the cerebral cortex during @entity3303 -induced @entity410 .
